Philadelphia University + Thomas Jefferson University


Highlighted Publications

Magee MS, Kraft CL, Abraham TS, Baybutt TR, Marszalowicz GP, Li P, Waldman SA, Snook AE. GUCY2C-directed CAR-T cells oppose colorectal cancer metastases without autoimmunity. Oncoimmunology. 2016;5:e1227897. PMID 27853651, PMCID PMC5087292

This paper shows that CAR-T cells targeting GUCY2C treat metastatic colorectal cancer without cause toxicity in GUCY2C-expressing tissues. PDF: Magee-2016-OncoImmunology

Snook AE, Magee MS, Schulz S, Waldman SA. Selective antigen-specific CD4(+) T-cell, but not CD8(+) T- or B-cell, tolerance corrupts cancer immunotherapy. Eur J Immunol. 2014;44:1956-66. PMID 24771148, PMCID PMC4107120

This paper shows that GUCY2C-specific self-tolerance is mediated by selective CD4+ T-cell tolerance which can be exploited to improve vaccine efficacy without impacting vaccine safety.  PDF: Snook-2014-Eur J Immunol

Snook AE, Li P, Stafford BJ, Faul EJ, Huang L, Birbe RC, Bombonati A, Schulz S, Schnell MJ, Eisenlohr LC, Waldman SA. Lineage-specific T-cell responses to cancer mucosa antigen oppose systemic metastases without mucosal inflammatory disease. Cancer Res. 2009;69:3537-44. PMID 19351847, PMCID PMC2707278

This paper shows that GUCY2C vaccination safely induces antitumor immunity without autoimmunity.  PDF: Snook-2009-Cancer Res

Snook AE, Stafford BJ, Li P, Tan G, Huang L, Birbe R, Schulz S, Schnell MJ, Thakur M, Rothstein JL, Eisenlohr LC, Waldman SA. Guanylyl cyclase C-induced immunotherapeutic responses opposing tumor metastases without autoimmunity. J Natl Cancer Inst. 2008;100:950-61. PMID 18577748, PMCID PMC2749952

This paper demonstrates that GUCY2C is a potential cancer vaccine target.  PDF: Snook-2008-J Natl Cancer Inst

Recent Publications

Human GUCY2C-targeted chimeric antigen receptor (CAR)-expressing T cells eliminate colorectal cancer metastases

Immunotherapy regimens for metastatic colorectal carcinomas

CD4+T cells: The nexus of tolerance, autoimmunity and tumor immunity

Immunotherapy in Colorectal Cancer: Where Are We Now?

The heat-stable enterotoxin receptor, guanylyl cyclase C, as a pharmacological target in colorectal cancer immunotherapy: A bench-to-bedside current report

GUCY2C signaling opposes the acute radiation-induced GI syndrome

ST-producing E. Coli oppose carcinogen-induced colorectal tumorigenesis in mice

Guanylate cyclase C as a target for prevention, detection, and therapy in colorectal cancer

The swinging pendulum of cancer immunotherapy personalization

Prime-boost immunization eliminates metastatic colorectal cancer by producing high-Avidity effector CD8+T cells

siRNA-Encapsulated Hybrid Nanoparticles Target Mutant K-ras and Inhibit Metastatic Tumor Burden in a Mouse Model of Lung Cancer

RB loss promotes prostate cancer metastasis

EXECUTIVE INTERVIEW - Viral gene: Protein-targeting cancer vaccine could boost survival rates

GUCY2C maintains intestinal LGR5+stem cells by opposing ER stress

Preclinical Evaluation of a Replication-Deficient Recombinant Adenovirus Serotype 5 Vaccine Expressing Guanylate Cyclase C and the PADRE T-helper Epitope

GUCY2C-directed CAR-T cells oppose colorectal cancer metastases without autoimmunity

Guanylyl cyclase C hormone axis at the intersection of obesity and colorectal cancer

Targeting guanylate cyclase C in colorectal cancer: Where are we now?

Obesity-induced colorectal cancer is driven by caloric silencing of the guanylin-GUCY2C paracrine signaling axis

A novel role for Cish in the inhibition of TCR signaling